309 related articles for article (PubMed ID: 26364916)
1. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
3. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
4. Chitosan nanoparticle-based delivery of fused NKG2D-IL-21 gene suppresses colon cancer growth in mice.
Tan L; Han S; Ding S; Xiao W; Ding Y; Qian L; Wang C; Gong W
Int J Nanomedicine; 2017; 12():3095-3107. PubMed ID: 28450784
[TBL] [Abstract][Full Text] [Related]
5. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
6. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
7. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
8. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 10 decreases MICA expression on melanoma cell surface.
Serrano AE; Menares-Castillo E; Garrido-Tapia M; Ribeiro CH; Hernández CJ; Mendoza-Naranjo A; Gatica-Andrades M; Valenzuela-Diaz R; Zúñiga R; López MN; Salazar-Onfray F; Aguillón JC; Molina MC
Immunol Cell Biol; 2011 Mar; 89(3):447-57. PubMed ID: 20714339
[TBL] [Abstract][Full Text] [Related]
10. Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease.
Boukouaci W; Al-Daccak R; Dulphy N; Lauden L; Amokrane K; Fortier C; Marzais F; Bennabi M; Peffault de Latour R; Socie G; Toubert A; Charron D; Krishnamoorthy R; Tamouza R
Hum Immunol; 2013 Dec; 74(12):1536-41. PubMed ID: 23994587
[TBL] [Abstract][Full Text] [Related]
11. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA.
Wan LL; Zhang DQ; Zhang JN; Ren LQ
J Zhejiang Univ Sci B; 2017 Jun; 18(6):522-531. PubMed ID: 28585428
[TBL] [Abstract][Full Text] [Related]
12. Delivery of human NKG2D-IL-15 fusion gene by chitosan nanoparticles to enhance antitumor immunity.
Yan C; Jie L; Yongqi W; Weiming X; Juqun X; Yanbing D; Li Q; Xingyuan P; Mingchun J; Weijuan G
Biochem Biophys Res Commun; 2015 Jul; 463(3):336-43. PubMed ID: 26022121
[TBL] [Abstract][Full Text] [Related]
13. NKG2D-IL-15 fusion protein encapsulated in N-[(2-hydroxy-3-trimethylammonium) propyl] chitosan chloride retards melanoma growth in mice.
Chen R; Ding Y; Xi J; Lu G; Xiao W; Ding Y; Qian L; Lin Z; Gong W
Transl Cancer Res; 2019 Oct; 8(6):2230-2241. PubMed ID: 35116976
[TBL] [Abstract][Full Text] [Related]
14. NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma.
Wang T; Sun F; Wang Y; Jiang J; Pan M; Yuan M; Zhang H; Du X; Hezam K; Song K; Wang M; Zhang J
J Immunother; 2018 Apr; 41(3):109-117. PubMed ID: 29528990
[TBL] [Abstract][Full Text] [Related]
15. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
Tietje A; Li J; Yu X; Wei Y
Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
[TBL] [Abstract][Full Text] [Related]
16. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer.
Xie W; Liu F; Wang Y; Ren X; Wang T; Chen Z; Tang M; Sun F; Li Z; Wang M; Zhang J
Oncotarget; 2016 Mar; 7(13):16445-61. PubMed ID: 26909862
[TBL] [Abstract][Full Text] [Related]
17. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
18. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
20. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
